Drug Trial Radar · NCT06634420
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Actual
Start
Jan 15, 2025
Primary completion
Feb 10, 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Intellia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Conditions
- Hereditary Angioedema
Interventions
NTLA-2002Biological
CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
Normal Saline IV AdministrationBiological
The administration of intravenous (IV) normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-normalized number of Investigator-confirmed HAE attacksTime frame: From Week 5 through Week 28
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
Medical Research of Arizona
Scottsdale, Arizona
University of California, San Diego (UCSD)
San Diego, California
Raffi Tachdjian MD, Inc
Santa Monica, California
Allergy & Asthma Clinical Research
Walnut Creek, California
IMMUNOe International Research Centers
Centennial, Colorado
Asthma & Allergy Associates
Colorado Springs, Colorado
University of South Florida
Tampa, Florida
Massachusetts General Hospital
Boston, Massachusetts
Washington University in St. Louis
St Louis, Missouri
NYU Langone Health - Long Island
Mineola, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
AARA Research Center
Dallas, Texas
Campbelltown Hospital
Campbelltown, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
University of Alberta
Edmonton, Alberta, Canada
Ottawa Allergy Research Corporation
Ottawa, Ontario, Canada
CHU Grenoble-Alpes - Hopital Michallon
Grenoble, France
CHU de Lille - Hopital Claude Huriez
Lille, France
AP-HM - Hopital de la Timone
Marseille, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet
Frankfurt, Germany
Medizinische Hochschule Hannover (MHH)
Hanover, Germany
Amsterdam UMC - Locatie AMC
Amsterdam, Netherlands
New Zealand Clinical Research (NZCR)
Auckland, New Zealand
University of Cape Town - Lung Institute - Lung Clinical Research Unit
Cape Town, South Africa
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.